 | | Vol. 9.35 – 16 September, 2020 |
| |
|
|
| Researchers demonstrated that metabolic reprogramming induced by mitochondrial fusion was rate-limiting for immortalization of tumor-initiating cells and triggered their irreversible dedication to tumorigenesis.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists established regionally derived models of glioblastoma edge and core that retained their spatial identity in a cell autonomous manner.
[Nature Communications] |
|
|
|
| Researchers presented a novel approach to target and reduce the frequency of aldehyde dehydrogenase (ALDH)high CSCs by vaccination against ALDH.
[Nano Letters] |
|
|
|
| Investigators demonstrated the dual-targeted delivery and enhanced therapeutic effect of eHNP-A1-CD15-LDE225 via scavenger receptor class B type 1 and CD15 on brain sonic hedgehog subtype of medulloblastoma cells in vitro, ex vivo, and in vivo.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists found that the stress-like subpopulation of cancer cells was present from the early stages of tumorigenesis.
[Cell Systems] |
|
|
|
| When dynamically labeling breast cancer cells along cancer progression, investigators observed that the majority of circulating tumor cells (CTCs) clusters undergone hypoxia, while single CTCs were largely normoxic.
[Cell Reports] |
|
|
|
| Researchers presented a therapeutically relevant crosstalk between Hedgehog signaling and the glucocorticoid receptor pathway acting at the level of GLI1 transcription factor.
[Oncogene] |
|
|
|
| The authors demonstrated that carnitine palmitoyltransferase I (CPT1A), a key enzyme controlling fatty acid oxidation, was upregulated in colon cancer cells upon exposure to adipocytes or fatty acids.
[Cell Death & Disease] |
|
|
|
| Scientists identified a mechanism of radioresistance mediated by linc-RA1 (radioresistance-associated long intergenic noncoding RNA 1). Linc-RA1 was upregulated in radioresistant glioma cells and glioma tissue samples, compared with radiosensitive cells and nontumor tissues.
[Cell Death & Disease] |
|
|
|
| Investigators showed that prostate cancer stem-like cells also colonizing prostate-draining lymph nodes of transgenic adenocarcinoma of the mouse prostate mice overexpressed galectin 3.
[Frontiers in Immunology] |
|
|
|
| Researchers hypothesized that tumor relapse after the selective targeting of CSCs was due to intermediate progenitor cells that maintained the tumor volume. In order to support this hypothesis, they implemented a mathematical model derived using pseudo-reactions representing the events of each cell subpopulation within the tumor.
[Cancers] |
|
|
|
| Scientists clarified the potential involvement of long non-coding RNA SNGH3 in the acquisition of cisplatin resistance and stemness in gastric cancer.
[Cellular Oncology] |
|
|
|
|
| The authors describe key chromatin regulatory pathways disrupted in gliomas, delineating their physiological function and the current understanding of how their dysregulation may contribute to gliomagenesis.
[Cancer Cell] |
|
|
|
| Investigators provide a sketch of the inhibiting roles of current chloroquine analogues and antibiotic combination in CSC autophagy process and discuss the possibility that pre‐clinical and clinical potential therapeutic strategy for anticancer therapy.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| The authors discuss the multifaceted contribution of microRNAs, long non-coding RNAs, and circular RNAs, as representative ncRNA classes, in sustaining the CSC-like traits, as well as the underlying molecular mechanisms of their action in various CSC types.
[International Journal of Molecular Sciences] |
|
|
|
|
| Ryvu Therapeutics announced that the first patient had been treated in Europe for the cohort expansion part of Phase II DIAMOND-01 clinical trial investigating SEL24/MEN1703, a first-in-class, oral dual PIM/FLT3 inhibitor, as single agent in acute myeloid leukemia.
[Ryvu Therapeutics] |
|
|
|
| Mateon Therapeutics announced that the FDA designated OXi4503 for treatment of acute myeloid leukemia due to genetic mutations that disproportionately affected pediatric patients as a drug for a “rare pediatric disease,” as defined in section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act.
[Mateon Therapeutics] |
|
|
|
|
|
|
|
| | The University of Georgia – Athens, Georgia, United States |
|
|
|
| | Karolinska Institute – Solna, Sweden |
|
|
|
| | Karolinska Institute – Solna, Sweden |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York City, New York, United States |
|
|
|
| | St. Anna Children’s Cancer Research Institute – Vienna, Austria |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Umbilical & Placental Cell News
